Morgan Stanley lifted its position in shares of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) by 1,324.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 262,144 shares of the company’s stock after purchasing an additional 243,746 shares during the quarter. Morgan Stanley owned about 0.51% of Osmotica Pharmaceuticals worth $1,418,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in OSMT. American International Group Inc. boosted its position in shares of Osmotica Pharmaceuticals by 40.2% during the second quarter. American International Group Inc. now owns 7,308 shares of the company’s stock valued at $49,000 after purchasing an additional 2,094 shares in the last quarter. Bank of America Corp DE raised its stake in Osmotica Pharmaceuticals by 291.4% during the second quarter. Bank of America Corp DE now owns 11,695 shares of the company’s stock valued at $79,000 after buying an additional 8,707 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new position in Osmotica Pharmaceuticals during the third quarter valued at $85,000. Forefront Analytics LLC purchased a new position in Osmotica Pharmaceuticals during the third quarter valued at $111,000. Finally, Nuveen Asset Management LLC purchased a new position in Osmotica Pharmaceuticals during the second quarter valued at $154,000. Institutional investors own 11.89% of the company’s stock.
Shares of OSMT opened at $4.44 on Thursday. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.17 and a quick ratio of 2.83. Osmotica Pharmaceuticals plc has a one year low of $2.81 and a one year high of $9.67. The firm has a market capitalization of $228.75 million, a P/E ratio of -1.52 and a beta of 3.27. The business has a fifty day moving average of $5.33 and a 200 day moving average of $5.71.
OSMT has been the subject of a number of recent research reports. Zacks Investment Research cut Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 5th. BidaskClub cut Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 23rd. ValuEngine upgraded Osmotica Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 23rd. Finally, Truist decreased their price target on Osmotica Pharmaceuticals from $11.00 to $8.00 in a research note on Wednesday, December 30th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.58.
Osmotica Pharmaceuticals Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity.
Read More: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.